- Home
- VYGR vs ZYXI Comparison
VYGR vs ZYXI Comparison
Compare VYGR & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- ZYXI
- Stock Information
- Founded
- VYGR 2013
- ZYXI 1996
- Country
- VYGR United States
- ZYXI United States
- Employees
- VYGR N/A
- ZYXI N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VYGR Health Care
- ZYXI Health Care
- Exchange
- VYGR Nasdaq
- ZYXI Nasdaq
- Market Cap
- VYGR 222.9M
- ZYXI 261.5M
- IPO Year
- VYGR 2015
- ZYXI N/A
- Fundamental
- Price
- VYGR $3.41
- ZYXI $2.18
- Analyst Decision
- VYGR Strong Buy
- ZYXI Buy
- Analyst Count
- VYGR 9
- ZYXI 3
- Target Price
- VYGR $14.86
- ZYXI $10.25
- AVG Volume (30 Days)
- VYGR 360.5K
- ZYXI 509.1K
- Earning Date
- VYGR 03-11-2025
- ZYXI 03-11-2025
- Dividend Yield
- VYGR N/A
- ZYXI N/A
- EPS Growth
- VYGR N/A
- ZYXI N/A
- EPS
- VYGR N/A
- ZYXI 0.09
- Revenue
- VYGR $80,001,000.00
- ZYXI $192,354,000.00
- Revenue This Year
- VYGR N/A
- ZYXI $27.05
- Revenue Next Year
- VYGR $23.46
- ZYXI $20.89
- P/E Ratio
- VYGR N/A
- ZYXI $25.00
- Revenue Growth
- VYGR N/A
- ZYXI 4.36
- 52 Week Low
- VYGR $3.56
- ZYXI $2.24
- 52 Week High
- VYGR $10.66
- ZYXI $12.84
- Technical
- Relative Strength Index (RSI)
- VYGR 28.74
- ZYXI 12.56
- Support Level
- VYGR $3.58
- ZYXI $2.41
- Resistance Level
- VYGR $3.96
- ZYXI $2.64
- Average True Range (ATR)
- VYGR 0.25
- ZYXI 0.35
- MACD
- VYGR -0.01
- ZYXI -0.04
- Stochastic Oscillator
- VYGR 2.60
- ZYXI 1.33
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.